Skip to main content

Table 1 Demographic data and laboratory findings at baseline in four subgroups of rheumatoid arthritis patients according to therapeutic agents used

From: Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis

  Adalimumab (n = 32) Etanercept (n = 16) Tocilizumab (n = 24) Without biologic (n = 20)
Mean age, years 53.5 ± 12.6 54.4 ± 7.8 56.8 ± 14.4 57.0 ± 11.4
Female proportion 28 (87.5%) 13 (81.3%) 20 (83.3%) 17 (85.0%)
Disease duration, years 13.4 ± 6.6 13.6 ± 9.0 13.0 ± 9.7 12.3 ± 5.8
Body mass index, kg/m2 24.8 ± 4.6 23.6 ± 4.5 24.5 ± 3.7 22.9 ± 2.9
RF positivity 28 (87.5%) 13 (81.3%) 17 (70.8%) 14 (70.0%)
Anti-CCP positivity 21 (65.6%) 11 (68.8%) 17 (70.8%) 15 (75.0%)
Baseline ESR, mm/1st hour 33.5 ± 23.4 39.0 ± 36.0 42.5 ± 30.0 35.8 ± 22.1
Baseline DAS28 5.46 ± 0.94 5.48 ± 0.98 5.80 ± 0.85 5.12 ± 0.59
Daily steroid dose, mg/day 6.3 ± 2.5 6.9 ± 1.9 7.4 ± 2.1 7.0 ± 2.2
DMARDs at baseline     
  MTX, weekly dose, mg 12.0 ± 2.5 10.6 ± 3.7 11.5 ± 2.5 11.3 ± 2.8
  Sulfasalazine 27 (84.4%) 12 (75.0%) 18 (75.0%) 17 (85.0%)
  Hydroxychloroquine 24 (75.0%) 12 (75.0%) 19 (79.2%) 18 (90.0%)
  Cyclosporine 6 (18.7%) 4 (25.0%) 5 (20.8%) 7 (35.0%)
Hypertension 14 (43.8%) 6 (37.5%) 8 (33.3%) 8 (40.0%)
Antihypertensive Rx 8 (25.0%) 4 (25.0%) 7 (29.2%) 6 (30.0%)
Diabetes mellitus 2 (6.2%) 1 (6.3%) 1 (4.2%) 1 (5.0%)
Hypoglycemic Rx 1 (3.1%) 1 (6.3%) 0 (0.0%) 0 (0.0%)
Current smoker 3 (9.4%) 2 (16.6%) 3 (12.5%) 3 (15.0%)
  1. Data are presented as mean ± standard deviation or as number (percentage). anti-CCP, anti-cyclic citrullinated peptide (antibodies); DAS28, disease activity score for 28 joints; DMARDs, disease-modifying anti-rheumatic drugs; ESR, erythrocyte sedimentation rate; MTX, methotrexate; RF, rheumatoid factor; Rx, treatment.